<DOC>
	<DOC>NCT02545465</DOC>
	<brief_summary>The aim of this study is to understand the treatment patterns in patients with Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH) during a switch of treatment to Adempas in real-life clinical practice. In addition, this study will describe patient demographics and reason for switching</brief_summary>
	<brief_title>A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<criteria>Female and male adult patients diagnosed with PAH or inoperable/recurrent/persistent CTEPH who have been switched from a PH treatment (i.e. Endothelin Receptor Antagonist(ERAs), Phosphodiesterase5 inhibitor(PDE5i) or Prostacyclin Analog (PCA) to Adempas Patients participating in an investigational program with interventions outside of routine clinical practice Patients who have not switched their therapy from an Endothelin Receptor Antagonist (ERA) or Prostacyclin Analog (PCA) but received Adempas purely as an addon therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>Inoperable Chronic Thromboembolic Pulmonary Hypertension</keyword>
	<keyword>Persistent Chronic Thromboembolic Pulmonary Hypertension</keyword>
	<keyword>Recurrent Chronic Thromboembolic Pulmonary Hypertension</keyword>
	<keyword>Switch of therapy</keyword>
	<keyword>Titration phase</keyword>
	<keyword>Retrospective chart review</keyword>
</DOC>